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Abstract
Paracoccidioidomycosis (PCM), endemic in Latin America, is a progressive systemic mycosis caused by Paracoccidioides
brasiliensis (P. brasiliensis), which primarily attacks lung tissue. Dendritic cells (DCs) are able to initiate a response in naı¨ve T
cells, and they also participate in Th-cell education. Furthermore, these cells have been used for therapy in several disease
models. Here we transfected DCs with a plasmid (pMAC/PS-scFv) encoding a single chain variable fragment (scFv) of an anti-
Id antibody that is capable of mimicking gp43, the main antigenic component of P. brasiliensis. First, Balb/c mice were
immunized subcutaneously with pMAC/PS-scFv and, after seven days, scFv protein was presented to the regional lymph
nodes cells. Moreover, we showed that the DCs transfected with scFv were capable of efficiently activating proliferation of
total lymph node cells and inducing a decrease in lung infection. Therefore, our results suggested that the use of scFv-
transfected DCs may be a promising therapy in the paracoccidioidomycosis (PCM) model.
Citation: Ferreira KS, Maranha˜o AQ, Garcia MCC, Brı´gido MM, Santos SS, et al. (2011) Dendritic Cells Transfected with scFv from Mab 7.B12 Mimicking Original
Antigen gp43 Induces Protection against Experimental Paracoccidioidomycosis. PLoS ONE 6(1): e15935. doi:10.1371/journal.pone.0015935
Editor: Kirsten Nielsen, University of Minnesota, United States of America
Received September 22, 2010; Accepted December 2, 2010; Published January 7, 2011
Copyright:  2011 Ferreira et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Fundac¸ao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP Process: 07/57594-9)(scholarship to K.S.F.
process: 07/50568-2) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, research fellowships to S.R.A. and J.D.L.). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: karenspadari@gmail.com
Introduction
Paracoccidioidomycosis (PCM) is a mycotic disease caused by a
terminally dimorphic fungus Paracoccidioides brasiliensis (P. brasilien-
sis), which initiates a deep mycosis and a primary attack on the
lung tissue. Epidemiological and experimental evidence suggests
that natural infection is initiated after inhalation of the conidia
produced by the mycelial form of the fungus [1].
The main antigenic component of the P. brasiliensis is a 43-kDa
glycoprotein that has been shown to elicit strong antibody and
cellular immune responses in human and experimental models
[2,3]. Antibodies against this glycoprotein can be detected during
all stages of the disease. The analysis of the isotype representation
of the IgG reactivity indicated that the two forms of the disease
(sub-acute and chronic) have distinct profiles. IgG4 reactivity was
associated with the sub-acute form and IgG2 was only seen in
chronic form patients [4]. Based on the knowledge that a
conversion to IgG4 is dependent on interleukin-4 and that the
conversion to IgG2 is influenced by interferon-c [5,6], it is
suggested that the sub-acute form is related to a Th2-type pattern
of immune response, while a chronic form is related to a protective
response (Th1-type) in the PCM disease.
According to the network hypothesis proposed by Jerne et al
[7], anti-idiotypic (anti-Id) antibodies are a component of the
normal immune response, which results in a web of interacting
idiotypic (Id) antibodies. Id are the sum of idiotopes or
serologically determined antigenic determinants unique to an
antibody or group of antibodies [8,9]. Anti-Id antibodies recognize
antigenic determinants that overlap in the combining site that is in
contact with the original antigen; thus, they are supposed to carry
its ‘‘internal image’’. Although those anti-Id antibodies, also
known as Ab2-b, are able to mimic the antigen, they represent a
small fraction of all anti-Id antibodies produced [10,11]. Previous
research showed that mice immunized with anti-gp43 monoclonal
antibodies (Mabs) (Ab1) unleashed the idiotypic cascade and
produced both anti-Id antibodies (Ab2) as well as anti-anti-Id
antibodies (Ab3). Ab2 Mabs named 7.B12 inhibited (.95%) the
binding of gp43 to Mab 17C (Ab1), suggesting that this anti-Id
Mab bound to the idiotope, thus fulfilling the ‘‘internal image’’
criteria proposed by Nisonoff and Lamoyi [12]. To elucidate
whether the Ab2-b Mab (7.B12), rather than gp43, may act as an
antigen in serological assays, the sera from PCM patients were
tested. An ELISA test using Ab2-b bound to the solid phase
allowed for the serological monitoring of patients after antifungal
therapy, and the test produced an equivalent curve when
compared with an ELISA that employed purified gp43. We also
observed a T-cell proliferation response when mice were
immunized with Ab2-b and when their cells were exposed to
gp43 in vitro [13]. Previous studies showed that anti-Id are superior
to peptides or antigens in inducing viral epitopes to CD4+ T cells
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activation by APCs [14]. Therefore, we suggested that Ab2-b
7.B12, which contains a T-cell epitope, may be used in a
protection assay.
Antibody based therapy has gained increased acceptance with
several Mabs currently used as therapeutic agents or in late stage
clinical trials [15]. However, Mabs of either human or mouse
origin may remain in the circulation and can generate unwanted
reactions. The possibility of genetic variations introduced during
repeated cycles of cell growth makes Mabs difficult to handle and
potentially unreliable. Intact antibodies are known, due to their
size, to remain in the circulation causing putative damage
systematically or in non-targeted organs [16].
On the other hand, antibody fragments such as single-chain
variable fragments (scFv) may be the smallest antigen-binding
fragments, and they were originally developed to simplify the
expression of antigen-binding fragments [17–19]. Also, scFv has
been employed in several therapeutic models [20–23]. Dendritic
cells (DCs) strongly upregulate the expression of costimulatory
molecules and production of cytokines, and thus, they constitute
the most potent antigen presenting cells (APCs), which are capable
of stimulating naı¨ve antigen-specific T cells and inducing a
primary immune reaction. In addition, these cells have been used
for therapy in several disease models [24]. Strategies that have
been used to adapt this biological potential to therapy include
manipulating DCs by co-culturing (pulsing) with whole antigens,
defined antigenic peptides or total RNA, or genetically modifying
DCs with genes encoding specific antigens. Among these
strategies, genetically modifying DCs with genes encoding specific
tumor antigens is a potential therapy. Therefore, in this study, we
transfected DCs with scFv from Mab 7.B12 (Ab2-b). Our
constructs had the typical structure of scFv, with the variable
domain of the immunoglobulin heavy chain (VH) linked to the
light chain (VL) via a flexible peptide linker in a VH-VL
orientation [25]. We showed that DCs transfected with scFv were
capable of efficiently activating the proliferation of total lymph
node cells and inducing a decrease in lung infection. The
engineering of scFv associated with DCs is a promising therapy
in the experimental PCM model.
Results
Cloning and expression of Ab2-b Mab scFv in
mammalian cells
Ab2-b Mab VH and VL domain gene sequences were
determined and sub-cloned into the pIg16 vector [19] to enable
the assembly of scFv. The scFv gene was then transferred to the
pMAC/PS vector so that it could be expressed in mammalian
cells. The expression cassette is shown in Figure 1.
To assess its transient expression in mammalian cells, the scFv
protein was measured in the culture supernatants of transfected
CHO cells. After 48 hours, the supernatants were collected, and
scFv secretion was measured by dot immunoblotting. We detected
scFv in only supernatants from pMAC/PS-scFv-transfected CHO
cells and not in supernatants from the controls (empty vector-
transfected or non-transfected CHO cells) (Figure 2).
scFv gene expression
DCs have the capacity to recognize, capture, process and
present antigen, and to migrate to the lymph nodes and activate T
lymphocytes through antigen presentation. To analyze the
capacity of these cells to specifically respond to a DNA
immunization through migration to the lymph nodes and
expressing the Ab2-b Mab scFv, we intramuscularly immunized
BALB/c mice with cardiotoxin, a potent adjuvant that induce a
local inflammatory stimulus, five days before they received an
intramuscular injection of the pMAC/PS-scFv or the empty
vector. After 24 hours, we removed the inguinal and popliteal
lymph nodes to verify the expression of the scFv gene. For this
analysis, we extracted total RNA from the lymph nodes and
measured the scFv expression by employing real-time PCR with
specific primers for the VH counterpart of the scFv gene. The
results showed that scFv gene expression increased only in animals
that received pMAC/PS-scFv. In the controls, which received only
the cardiotoxin stimulus or the empty vector, there was no increase
in gene expression (Figure 3).
DCs transfected with pMAC/PS-scFv stimulated lymph
node cells in vivo
To analyze the percentage of transfected DC, the cells were co-
transfected with a GFP-Neo vector, and the result was determined
by percentage of fluorescence cell. Our date showed that the
transfection was approximately 80% successful (Figure 4 A). After
that, to verify the capacity of DCs in presenting antigen and
activating T cells, BALB/c mice were intramuscularly immunized
with DCs transfected with pMAC/PS (control) or pMAC/PS-
scFv. One week later, the popliteal and inguinal lymph nodes were
collected and cultivated in vitro in the presence of different
concentrations of Ab2-b Mab (5, 10 and 15 mg/mL) or 10 mg of
gp43. The results showed that DCs transfected with pMAC/PS-
scFv induced a significant proliferative response mainly in the
presence of 10 mg/mL of the antibody. We also observed that
re-stimulation in vitro with gp43 led to significant proliferation only
in lymph node cells from mice that received pMAC/PS scFv
immunization (Figure 4 B).
Figure 1. Design of scFv in pMAC/PS vector. The mammalian
expression plasmid pMAC/PS drives the expression of scFv using the
human CMV immediate early promoter. We show the schematic
representation of the scFv expression cassette, highlighting the
restriction sites added. The coding regions were: VH for heavy variable
domain; VL for light variable domain; H for six histidine tags; SS for
signal sequence; S for Sma I; X for Xba I; B for Bgl II; and N for Nco I.
doi:10.1371/journal.pone.0015935.g001
Figure 2. scFv production in transfected CHO cells. CHO cells
were transfected with pMAC/PS (empty vector) or pMAC/PS-scFv and
after 48 hours, the supernatants were collected, and the secretion of
scFv was measured by dot immunoblotting. Supernatants from non-
transfected CHO cell were used as the control (NT).
doi:10.1371/journal.pone.0015935.g002
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Immunotherapy
To analyze whether DCs transfected with pMAC/PS-scFv were
capable of inducing an efficient therapeutic effect, BALB/c mice
were intratracheally infected with 16106 of Pb18 virulent yeast.
After 14 and 21 days, they were treated intramuscularly with PBS,
DCs, DC-pMAC/PS or DC-pMAC/PS-scFv. One week after the
last treatment, the animals were sacrificed, and the lungs were
collected for CFU analysis. The results showed a significant
decrease in fungal growth only in animals treated with DCs
transfected with pMAC/PS-scFv when we compared with the
groups of animals that received PBS, DCs, or DCs transfected with
pMAC/PS (Figure 5).
Discussion
Infection with P. brasiliensis remains one of the main fungal
infections in Latin America. Thus, the need to develop a novel
immunotherapeutic model for this infection is important to public
health. In this investigation, we engineered a scFv from the Ab2-b
of the gp43 protein of P. brasiliensis and transfected it into DCs to
investigate the capacity of these cells to efficiently induce a
therapeutic effect in an experimental PCM model.
An important problem to be resolved in the PCM is the
treatment. Frequently, several years of treatment are required and
in the some case are not effective. Sulfonamides, ketaconazole,
itraconazole, fluconazole and anphotericin B have been used in
the treatment of PCM [26]. However, the treatment is long and
hepatotoxic, then, the search for new alternatives for treating is
necessary. Novel treatments may be found among new classes of
drugs, or agents capable of modulating the immune response, such
as scFv.
The scFv antibodies have been used in several immunothera-
peutic experiments. In particular, KT-scFv (yeast killer toxin)
exerted a therapeutic effect against Candida albicans rat vaginal
infection [27,28]. In serogroup B Neisseria meningitides (MenB), the
immunization with scFv from capsular polysaccharide showed the
potential of vaccination with genes encoding capsular mimics in
providing protection against MenB [29]. Along these lines, we
originally exploited the scFv derived from VH and VL domains of
Ab2-b Mab as a functional internal image of gp43 from P.
brasiliensis. Thus, we analyzed the antifungal activity when
transfected into DCs, which are the most potent APCs identified
thus far and are crucial for priming the immune response.
First, we analyzed whether a mammalian vector containing the
scFv (pMAC/PS-scFv) could express the protein in eukaryotic
cells. Therefore, we transfected the pMAC/PS-scFv into CHO
cells, and after 24 hours, we measured the secretion of scFv by dot
immunoblotting. Knowing that eukaryotic cells were able to
express and secrete scFv in vitro, we intramuscularly immunized
Balb/c mice with pMAC/PS-scFv, and after one day, we observed
the presence of scFv mRNA in popliteal and inguinal lymph
nodes.
Figure 3. Real-time PCR. Total inguinal and popliteal lymph node
cells were obtained after immunization with pMAC/PS-scFv. The mRNA
was extracted, and the expression of the scFv gene was measured by
real-time PCR using a specific primer for the VH counterpart of scFv. The
fold change was calculated based on GAPDH mRNA. Controls without
reverse transcriptase were used for each pair. *p,0.05 compared with
the controls (cardiotoxin or cardiotoxin plus empty pMAC). Results are
representative of 3 independent experiments in which 8 mice in each
group were used.
doi:10.1371/journal.pone.0015935.g003
Figure 4. Proliferative response. (A) percentage of DCs transfected; (B) Proliferation of lymph node cells from immunized mice with DC-pMAC-
scFv and re-stimulated in vitro with Ab2-b MAb (5, 10 and 15 mg/mL) or 10 mg of gp43. *p,0.05 compared with the control (DCs transfected with
pMAC/PS). Results are representative of 3 independent experiments in which 6 mice in each group were used. nd – not detected.
doi:10.1371/journal.pone.0015935.g004
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Following the intramuscular injection of a plasmid DNA
vaccine, most antigen expression occurs in transfected myocytes
at the site of injection [30]. Accumulating evidence, however,
suggests that immune priming is initiated by professional APCs
rather than by these myocytes [31–33]. Because professional APCs
are not typically found in normal muscle tissue, they presumably
migrate to the site of DNA inoculation in response to
inflammatory or chemotactic signals [34–36]. Infiltrating APCs
may then either take up the plasmid DNA directly or cross-present
the expressed antigen to initiate immune responses [37,38]. DCs
may be one of the APCs that migrate to the regional lymph nodes
because among all of the presenting cells, DCs are mainly
responsible for this process.
After observing that DNA-scFv immunization primed T cells in
vivo, we analyzed whether DCs could also efficiently present scFv
to all lymph node cells. For this experiment, we generated DCs
from the bone marrow and transfected them with pMAC/PS-
scFv. BALB/c mice were subcutaneously immunized twice with
these transfected DCs. The results showed that lymph node cells,
when re-stimulated in vitro with Ab2-b, were capable of inducing
proliferation, and we observed that scFv mimicked the original
gp43 antigen. According to several authors, DCs are one of the
most important cells responsible for activating an efficient immune
response, and these cells have been used as tumor treatments in
immunotherapy models [39,40].
DCs are an attractive target for therapeutic manipulation of the
immune system to enhance an otherwise insufficient immune
response to PCM. However, the complexity of the DC system
requires their rational manipulation to achieve therapeutic
immunity. Therefore, with scFv-transfected DCs, we reduced the
lung infection of BALB/c mice infected previously with virulent
Pb18 yeast. However, the mechanism of protection is unknown. An
efficient cellular immune response with IFNc-secreting CD4+ and
CD8+ T cells is responsible for the decrease of P. brasiliensis in the
organs during experimental infection. Some work has shown that
transfected DCs could activate both CD4+ and CD8+ T cells.
Shibagaki et al. used tumor-associated antigens containing the HIV
TAT protein transduction domain (PTD) to transduce DCs [41,42].
This fusion protein efficiently transduced DCs and was processed by
proteasomes for MHC class I-dependent presentation to cytotoxic T
lymphocytes. In addition, the TAT-containing antigen was also
presented to CD4+ T cells as efficiently as native antigen. Finally,
TAT-antigen-transduced DCs induced antigen-specific cytotoxic T
lymphocytes in vivo through vaccination against tumors [41,42].
Therefore, our results suggested an efficient T-cell activation may be
induced by using transfected DCs.
Thus, we conclude that immunotherapy based on DCs
transfected with scFv will become an essential component in
PCM experiments to decrease infection and activate T cells.
Materials and Methods
Ethics Statement
The protocol was approved by the Committee on the Ethics of
Animal Experiments of the Universidade de Sa˜o Paulo in 02/2008
(Permit Number: 168).
Mice
In the present study, we used 8- to 12-week-old female BALB/c
mice obtained from the animal laboratory facility of the University
of Sa˜o Paulo.
Paracoccidioides brasiliensis strains
The yeast form of the highly virulent P. brasiliensis strain 18
(Pb18) grown on Sabouraud agar (Neogen, Lansing-Michigan) was
used for the infection assays.
Preparation of fungal antigens
To purify gp43, the P. brasiliensis B-339 strain was prepared as
described by Gesztesi et al [43] and passed through an adsorbent
column consisting of murine anti-gp43 monoclonal antibody
(Mab) 17C (IgG2a, k light chain) [44] coupled to an Affi-gel 10
column (Bio-Rad Laboratories, Hercules, CA, USA). The gp43
protein was eluted with 0.1 M citric acid buffer (pH 2.8),
neutralized with 1 M Tris (pH 9.0), and further concentrated in
a 10K Amicon apparatus (Amicon Division, Beverly, MA, USA).
Protein content was determined using the Bradford method [45],
and each purification step was monitored by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [46].
Production of Mab Ab2-b 7.B12
A hybridoma was produced as described [11]. Large amounts of
Mab 7.B12 (IgG1, k light chain) were obtained by production of ascites
in BALB/c mice previously primed with Pristaine (Sigma-Aldrich,
St. Louis, USA). Mabs were purified from ascites fluids by affinity
chromatography in a Protein G column (Amersham – Uppsala,
Sweden). The antibodies were dialyzed against PBS and quantified.
Enrichment of DCs
Bone marrow-derived DCs were generated according to
described methods [47]. Femurs and tibias were flushed with 3–
5 ml of PBS in 1% BSA. Bone marrow cells were allowed to
differentiate into DCs through culturing in RPMI (Sigma-Aldrich,
St. Louis, USA) supplemented with 10% Fetal Calf Serum (FCS)
(Cultilab, Brasil), 10 mg/mL gentamicin (Schering-Plough, USA),
and recombinant cytokine GM-CSF (50 ng/mL) (Peprotech,
Brasil) for 7 days. On days 3 and 5, the nonadherent cells
(granulocytes and lymphocytes) were removed, and media and
growth factors were replaced. On day 7, the nonadherent cells
were removed and analyzed by FACS using DC cell surface
markers. More than 90% of the cells expressed CD11c+MHC
classII+ (data not shown).
Cloning and sequencing of 7.B12 variable regions
The hybridoma 7.B12 was grown in RPMI medium (Sigma-
Aldrich, St. Louis, USA) containing 10% FCS (Cultilab, Brazil).
Figure 5. Protection against Paracoccidioides brasiliensis infec-
tion. Animals were intratracheally infected with the same amount of
Pb18 virulent yeast. After 14 and 21 days, the experimental groups were
treated with PBS, DCs, DCs transfected with the empty vector (DC
pMAC) or DCs transfected with the scFv expression vector (DC pMAC-
scFv). After one week, the mice were sacrificed, and the Pb18 CFUs of
the lungs were determined. *p,0.05 compared with the controls
(treated with PBS, DCs or DC pMAC/PS). Results are representative of 3
independent experiments in which 6 mice in each group were used.
doi:10.1371/journal.pone.0015935.g005
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Approximately 106 cells were centrifuged and washed with PBS
(150 mM NaCl, 10 mM Na2H2PO4, pH 7.2). Total RNA was
isolated (TRIZOL, Invitrogen, Scotland, UK)), and the cDNAs
that encode the VH and VL domains were synthesized using the
SuperScript III Kit for RT-PCR (Invitrogen – Carlsbad, CA,
USA), according to the manufacturer’s instructions. For cDNA
synthesis, the 1.25-mM primers used were K18 (59TACAGTT-
GGTGCAGCATC39) for CK and c1 (59TGGACAGGGATC-
CAGAGTTCCAGGTCACT39) for Cc [48]. For the amplifica-
tion of the heavy and light chain V region, cDNAs were
synthesized using a library of sense primers previously described
[49,50], and the same anti-sense primers were used for cDNA
synthesis. The samples were subjected to 25 thermal cycles of 94uC
for 1 min and 72uC for 1 min. Amplified VH and VL cDNAs
were cloned into the pGEM-T easy vector (Promega, Madison,
WI) following the manufacturer’s instructions. Three clones of
each variable region were sequenced in both directions. DNA
sequencing reactions were performed using the DYEnamic ET
Dye Terminator Cycle Sequencing (MegaBACE) Kit and run on
the MegaBACE 500 Plus capillary sequencer.
scFv construction
Based on the sequence determined, new oligonucleotides were
designed and synthesized with the goal to clone the VH and VL
domains into the mammalian expression vector pMAC/PS, a
pMAC [51] that uses the cytomegalovirus IE1 promoter to drive
the expression of the scFv fused to a immunoglobulin signal
peptide. The primers were 59CCCGGGTGAAGCTGGTGGAG39
and 59TCTAGAGGAGACGGTGACCGTGG39 for VH and
59AGATCTCCAAATTGTTCTCACCCAGTC39 and 59CCAT-
GGTGATGATGGTGATGGTGTTTGATTTCCAGCTTGG39
for VL (NCBI reference sequence: HQ326123 for VL and
HQ322121 for VH). The generated amplicons harbored endonu-
clease sites (shown in italics) Sma I and Xba I for VH and Bgl II and
Nco I for VL. Additionally, a sequence encoding a His tag was
introduced in the VL 39(underlined). The amplified domain genes
were first cloned into the pIG 16 vector [19] for scFv assembly,
using SmaI and EcoRI restriction enzymes, and then, they were
transferred to the final vector pMAC/PS (http://www.unb.br/ib/
cel/imol/vetor/pMACPS.html).
scFv secretion
To analyze scFv production in mammalian cells, the protein
was detected in the culture supernatant of transfected Chinese
Hamster Ovarian (CHO) cells. The CHO cells were transfected
(using lipofectamine, Invitrogen – Carlsbad, CA, USA) with an
empty or scFv-carrying pMAC/PS vector. After 48 hours, the
supernatants were collected, and the analysis was performed using
dot immunoblotting. For this assay, 10 mL of the supernatants
were adsorbed to a nitrocellulose membrane (Hybond-C, GE-
Healthcare) and blocked with 1% BSA in PBS. After washes with
PBST (0.05% Tween 20 in PBS), the membrane was incubated
with a mouse anti-HIS antibody (1:2,500) (Sigma-Aldrich,
Carlsbad, CA, USA), followed by the addition of horseradish
peroxidase (HRP)-conjugated rabbit anti-mouse IgG (Thermo-
Scientific, 1:5,000). The membrane was developed with diamino-
benzidin (DABI) after the addition of mouse antibody anti-
immunoglobulin (anti-IgG) and marked with peroxidase (1:5000).
As a positive control, we used P. brasiliensis (Ab1, 20 ug/mL).
Proliferative response assay
Balb/c mice were immunized intramuscularly with DCs
transfected (JetPEI Macrophage, Polyplus transfection) with
pMAC/PS-scFv (16106 cells and 20 mg of vector with scFv).
One week later, the mice were sacrificed, and the inguinal and
popliteal lymph nodes were excised for cell isolation. For a
control, we used DCs transfected with an empty vector. To
calculate the percentage of transfected DC, the cells were co-
transfected with a GFP-Neo vector, and after 24 hours the
analysis was conducted using fluorescence microscopy. Lymph
node cell suspensions in complete medium were plated at a
concentration of 26105 cells per well in 96-well plates in the
presence of Ab2-b (5, 10 and 15 mg/mL) or 10 mg of gp43. Cells
were co-cultured for 72 h and then pulsed for 16 h with [3H]-
labeled thymidine (1 mCi/mL) (Amershan, UK). Cells were
collected with an automated cell harvester, and the incorporated
radioactivity was measured by liquid scintillation spectrometry.
The lymphoproliferation results were evaluated in accordance
with the incorporation of [3H]-labeled thymidine (Amershan,
UK). These results are presented as the mean counts per minute
(CPM) (PerkinElmer).
scFv gene expression in the lymph nodes
To analyze the capacity of DCs in presenting scFv in the
inguinal and popliteal lymph nodes, we intramuscularly immu-
nized BALB/c mice with 50 mL of the adjuvant cardiotoxin (7 mg/
animal) [52] five days before we injected the pMAC/PS-scFv
(10 mg/animal) or only the vector (10 mg/animal). After 24 hours,
we obtained the total lymph node cells, and total RNA was
extracted for real-time PCR using specific primers for the VH
counterpart of scFv (forward – 59GGGTCCGTGAAACTC-
TCCTG39 and reverse – 59CCCACTCCAGCCTCTTCTCT39)
domain of the antibody Ab2-b. As a control, we used specific
primers for murine GAPDH (forward – 59CCTGCACCAC-
CAACTGCTTA39 and reverse – 59AGTGATGGCATGGACT-
GTGG39) (NCBI Reference Sequence: NC_000072.5). For the
real-time PCR reactions, we used the SYBR GREEN Kit
(Invitrogen – Crlsbad, CA, USA) at concentrations recommended
by the manufacturer. The analysis was conducted using the F7500
real-time PCR (Applied Biosystem). The fold change was
calculated based on constitutive GAPDH mRNA levels. Controls
without reverse transcriptase were also run for each pair.
BALB/c therapy
Mice were challenged with an intratracheal inoculation of
16106 yeast cells of the virulent Pb 18 strain. After 21 and 28
days, the animals were treated in 4 differents groups and received
by intramuscular injection therapeutic doses of: Group 1: only
PBS (50 mL); Group 2: DCs (16106 cells); Group 3: DC-pMAC/
PS (16106 cells transfected with 20 mg of vector) or Group 4:
DCs -pMAC/PS-scFv (16106 cells transfected with 20 mg of
vector containing scFv). After seven days, all animals were
sacrificed, and the lungs were removed for colony forming unit
(CFU) analysis.
Statistics
Statistical comparisons were made by analysis of variance and
the Tukey-Kramer test. The mean and standard error (SE) values
are reported.
Author Contributions
Conceived and designed the experiments: KSF AQM MMB JDL SRA.
Performed the experiments: KSF MCCG SSS SRA. Analyzed the data:
KSF AQM MMB JDL SRA. Contributed reagents/materials/analysis
tools: AQM MMB SRA. Wrote the paper: KSF AQM MMC JDL SRA.
PCM Protection with scFv - Transfected DCs
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15935
References
1. Restrepo A, Tobo´n AM (2005) Paracoccidioides brasiliensis. in:, , Mandell GE,
Bennzett JE, Dollin R (2005) Principles and pratice of infectious diseases. 6 ed.
Philadelphia, PA: Elsevier. pp 3062–3068.
2. Franco MF, Mendes RP, Moscardi-Bacchi M, Rezkallah-Iwasso MT,
Montenegro MR (1989) Paracoccidioidomycosis. Bailliere’s Clin Trop Med
Commun Dis 4: 185–220.
3. Chang JT, Benjamin MS, Shevach EM (2000) Role of costimulation in the
induction of the IL-12/IL-2 receptor pathway and the development of
autoimmunity. J Immunol 164: 6.
4. Juvenale M, Derl Negro GM, Duart AJ, Bernard G (2001) Antibody isotypes to
a Paracoccidioides brasiliensis somatic antigen in sub-acute and chronic form
paracoccidioidomycosis. J Med Microbiol 50: 127–34.
5. Kitani A, Strober W (1993) Regulation of Cc subclass germ-line transcripts in
human peripheral blood B cells. J Immunol 151: 3478–88.
6. Kawano Y, Noma T (1996) Role of interleukin-2 and interferon-c in inducing
production of IgG subclass in lymphocytes of human newborns. Immunology
88: 40–48.
7. Jerne NK (1974) Towards a network theory of the immune system. Ann
Immunol (Paris) 125C: 373–389.
8. Jerne NK, Roland J, Cazenave PA (1982) Recurrent idiotopes and internal
images. EMBO J 1: 243–247.
9. Bona CA (1996) Internal image concept revisited. Proc Soc Exp Biol Med 213:
32–42.
10. Pan Y, Yuhasz SC, Amzel LM (1995) Anti-idiotypic antibodies: biological
function and structural studies. FASEB J 9: 43–49.
11. Souza AR, Gesztesi JL, Moraes JZ, Cruz CR, Sato J, et al. (1998) Evidence of
idiotypic modulation in the immune response to gp43, the major antigenic
component of Paracoccidioides brasiliensis in both mice and humans. Clin Exp
Immunol 114: 40–48.
12. Nisonoff A, Lamoyi E (1981) Implications of the presence of an internal image of
the antigen in anti-idiotypic antibodies: possible application to vaccine
production. Clin Immunol Immunopathol 21: 397–406.
13. Souza EB, Lopes JD, Almeida SR (2004) B and T cells responses eliceted by
monoclonal anti-idiotypic antibody (Ab2-beta) mimicking gp43 from Paracoc-
cidioides brasiliensis. Clin Exp Immunol 137: 123–8.
14. Zaghouani H, Kuzu Y, Kuzu H, Brumeanu TD, Swiggard WJ, et al. (1993)
Contrasting efficacy of presentation by major histocompatibility complex class-I
and class-II products when peptides are administered within a common protein
carrier, self immunoglobulin. Eur J Immunol 23: 2746–2750.
15. Depetris M, Casalis P, Kratje R, Etcheverrigaray M, Oggero M (2008) A ScFv
antibody fragment as a therapeutic candidate to neutralize abroad diversity of
human IFN-alpha subtypes. Journal of Immunological Methods 334: 104–113.
16. Erlandson A, Eriksson D, Johansson L, Riklund K, Stigbrand T, et al. (2006) In
vivo clearing of idiotypic antibodies with antiidiotypic antibodies and their
derivatives. Molecula Immunology 43: 599–606.
17. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, et al. (1988)
Single-chain antigen-binding proteins. Science 242: 423–426.
18. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, et al. (1988)
Protein engineering of antibody binding sites: recovery of specific activity in an
anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl
Acad Sci U S A 85: 5879–5883.
19. Brigido MM, Polymenis M, Stollar BD (1993) Role of mouse VH10 and VL
gene segments in the specific binding of antibody to Z-DNA, analyzed with
recombinant single chain Fv molecules. J Immunol 150: 469–479.
20. Abe H, Kuroki M, Tachibana K, Li T, Awasthi A, et al. (2002) Targeted
sonodynamic therapy of cancer using a photosensitizer conjugated with antibody
against carcinoembryonic antigen. Anticancer Res 22: 1575–1580.
21. Schwegler C, Dorn-Beineke A, Nittka S, Stocking C, Neumaier M (2005)
Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of
breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Cancer Res 65: 1925–1933.
22. He FT, Nie YZ, Chen BJ, Qiao TD, Fan DM, et al. (2002) Expression and
identification of recombinant soluble single-chain variable fragment of
monoclonal antibody MC3. World J Gastroenterol 8: 258–262.
23. Pignatari GC, Takeshita D, Parise CB, Soares FA, de Moraes JZ, et al. (2007)
Carcinoembryonic antigen (CEA) mimicry by an anti-idiotypic scFv isolated
from anti-Id 6.C4 hybridoma. J Biotechnol 127: 615–625.
24. Moll H, Berberich C (2001) Dendritic cell-based vaccination strategies:
induction of protective immunity against leishmaniasis. Immunobiology 204:
659–666.
25. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, et al. (1994)
Antibody fragments from a ‘single pot’ phage display library as immunochemical
reagents. EMBO J 13: 692–698.
26. Menezes VM, Soares BG, Fontes CJ (2006) Drugs for treating paracoccidioi-
domycosis. Cochrane Database Syst Rev 2: CD004967.
27. Beninati CM, Oggioni R, Boccanera M, Spinosa MR, Maggi T, et al. (2000)
Therapy of mucosal candidiasis by expression of an antiidiotype in human
commensal bacteria. Nat Biotechnol 18: 1060–1064.
28. Magliani W, Conti S, De Bernardes F, Gerloni M, Bertoletti D, et al. (1997)
Therapeutic potential of antiidiotypic single chain antibodies with yeast killer
toxin activity. Nat Biotechnol 15: 155–158.
29. Beninati C, Midiri A, Mancuso G, Biondo C, Arigo´ M, et al. (2006)
Antiidiotypic DNA vaccination induces serum bactericidal activity and
protection against group B meningococci. Journal of Experimental Medicine
203: 111–118.
30. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, et al. (1990) Direct
gene transfer into mouse nuscle in vivo. Science 247: 1465.
31. Warrens AN, Zhang JY, Sidhu S, Watt DJ, Lombardi G, et al. (1994) Myoblasts
fail to stimulate T cells but induce tolerance. Int Immunol 6: 847.
32. Doe B, Selby M, Barnett J, Walker CM (1996) Induction of cytotoxic T
lympocytes by intramuscular immunization with plasmid DNA is facilitated by
bone marrow-derived cells. Proc Natl Acad Sci USA 93: 8578.
33. Ulmer JB, Deck R, DeWitt CM, Donnelly JJ, Liu MA (1996) Generation of
MHC class-I-restricted cytotoxic T lymphocytes by expression of a viral protein
in muscle cells: antigen presentation by non-muscle cells. Immunology 89: 59.
34. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD (1996) DNA-
based immunization by in vivo transfection of dendritic cells. Nat Med 2: 1122.
35. Torres CA, Iwasaki A, Barber BH, Robinson HL (1997) Differential dependence
on target site tissue for gene gun and intramuscular DNA immunizations.
J Immunol 158: 4529.
36. Feltquate DM, Heaney S, Webster RG, Robinson HL (1997) Different T helper
cell types and antibody isotypes generated by saline and gene gun DNA
immunization. J Immunol 158: 2278.
37. Corr M, Lee DJ, Carson DA, Tighe H (1996) Gene vaccination with naked
plasmid DNA: mechanism of CTL priming. J Exp Med 184: 1555.
38. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH (1997) The
dominant role of bone marrow-derived cells in CTL induction following plasmid
DNA immuniztion at different sites. J Immunol 159: 11.
39. Boyle JS, Brady JL, Lew AM (1998) Enhanched responses to a DNA vaccine
encoding a fusion antigen that is directed to sites of immune induction. Nature
392: 408–411.
40. Palucka K, Banchereau J (2002) How dendritic cells and microbes interact to
elicit or subvert protective immune responses. Current Opinion in Immunology
14: 420–431.
41. Shibagaki N, Udey MC (2002) Dendritic cells transduced with protein antigens
induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 168:
2393–2401.
42. Shibagaki N, Udey MC (2003) Dendritic cells transduced with TAT protein
transduction domain-containing tyrosinase-related protein 2 vaccinate against
murine melanoma. Eur J Immunol 33: 850–860.
43. Gesztesi JL, Puccia R, Travassos LR, Vicentini AP, de Moraes JZ, et al. (1996)
Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidi-
oides brasiliensis modulate laminin-mediated fungal adhesion to epithelial cells
and pathogenesis. Hybridoma 15: 415–422.
44. De Camargo Z, Unterkircher C, Campoy SP, Travassos LR (1988) Production
of Paracoccidioides brasiliensis exoantigens for immunodiffusion tests. J Clin
Microbiol 26: 2147–2151.
45. Bradford MM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem 72: 248–254.
46. Laemmli VK (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 259: 680–685.
47. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. (1992) Generation of
large numbers of dendritic cells from mouse bone marrow cultures supplement-
ed with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:
1693–1697.
48. Caldas C, Coelho VP, Rigden DJ, Neschich G, Moro AM, et al. (2000) Design
and synthesis of germline-based hemi-humanized single-chain Fv against the
CD18 surface antigen. Protein Eng 13: 353–360.
49. Coloma MJ, Larrick JW, Ayala M, Gavilondo-Cowley JV (1991) Primer design
for the cloning of immunoglobulin heavy-chain leader-variable regions from
mouse hybridoma cells using the PCR. Biotechniques 11: 152–154, 156.
50. Zhou H, Fisher RJ, Papas TS (1994) Optimization of primer sequences for
mouse scFv repertoire display library construction. Nucleic Acids Res 22:
888–889.
51. Campos-da-Paz M, Costa CS, Quilici LS, de Carmo Simoes I, Kyaw CM, et al.
(2008) Production of recombinant human factor VIII in different cell lines and
the effect of human XBP1 co-expression. Mol Biotechnol 39: 155–158.
52. Pokorna D, Rubio I, Muller M (2008) DNA-vaccination via tattooing induces
stronger humoral and cellular immune responses than intramuscular delivery
supported by molecular adjuvants. Genetic Vaccines and therapy 6: 4.
PCM Protection with scFv - Transfected DCs
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15935
